How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants?

To reveal the source of oseltamivir-resistance in influenza (A/H5N1) mutants, the drug-target interactions at each functional group were investigated using MD/LIE simulations. Oseltamivir in the H274Y mutation primarily loses the electrostatic and the vdW interaction energies at the -NH(3)(+) and -OCHEt(2) moieties corresponding to the weakened hydrogen-bonds and changed distances to N1 residues. Differentially, the N294S mutation showed small changes of binding energies and intermolecular interactions. Interestingly, the presence of different conformations of E276 positioned between the -OCHEt(2) group and the mutated residue is likely to play an important role in oseltamivir-resistant identification. In the H274Y mutant, it moves towards the -OCHEt(2) group leading to a reduction in hydrophobicity and pocket size, whilst in the N294S mutant it acts as the hydrogen network center bridging with R224 and the mutated residue S294. The molecular details have answered a question of how the H274Y and N294S mutations confer the high- and medium-level of oseltamivir-resistance to H5N1.

[1]  M G Ford,et al.  Binding constants of neuraminidase inhibitors: An investigation of the linear interaction energy method. , 1999, Journal of medicinal chemistry.

[2]  Arieh Warshel,et al.  A surface constrained all‐atom solvent model for effective simulations of polar solutions , 1989 .

[3]  Supot Hannongbua,et al.  On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. , 2007, Biophysical journal.

[4]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[5]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[6]  T. Hansson,et al.  Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. , 1995, Protein engineering.

[7]  E. De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.

[8]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[9]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[10]  J. McKimm-Breschkin,et al.  Mechanisms of resistance of influenza virus to neuraminidase inhibitors , 2001 .

[11]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.

[12]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[13]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[14]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[15]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[16]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[17]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[18]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[19]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[20]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[21]  Jie J. Zheng,et al.  Computational studies of H5N1 influenza virus resistance to oseltamivir , 2009, Protein science : a publication of the Protein Society.

[22]  J. Åqvist,et al.  Q: a molecular dynamics program for free energy calculations and empirical valence bond simulations in biomolecular systems. , 1998, Journal of molecular graphics & modelling.

[23]  Thanyada Rungrotmongkol,et al.  Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1 , 2008, Proteins.

[24]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  A. Moscona,et al.  Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.

[26]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[27]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[28]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[29]  Thanyada Rungrotmongkol,et al.  Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation , 2009, Amino Acids.

[30]  G. Boivin,et al.  Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. , 2008, Antiviral research.

[31]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.